Immunomodulators of bacterial origin.
It stimulates both local cellular and humoral immune response in the mucosa of the respiratory tract and systemic immune response.
The preparation stimulates the activity of alveolar macrophages increases the number and activity of T lymphocytes, activates peripheral monocytes, increases the concentration of secretory IgA on the mucous membranes of the respiratory and digestive tracts, stimulates the production of protective adhesion molecules decreases the concentration of IgE antibodies in the blood increases cytokine production.
It reduces the frequency and severity of infections, thus reducing the need to use antibiotics.
For adults prescribed by a doctor, prescribed by a doctor Children, Children older than 12 years
1 kaps.liofilizirovanny bacterial lysate:
Moraxella catarrhalis 7 mg
propyl gallate (anhydrous)
sodium glutamate (anhydrous),
Tonsillitis, sinusitis, pharyngitis, rhinitis, laryngitis, bronchitis, respiratory tract infections, Otitis
- respiratory infections (in the complex therapy as an immunomodulatory agent) in children aged 6 months to 12 years (for capsules 3.5 mg);
- respiratory infections (in the complex therapy as an immunomodulatory agent) in adults and children over the age of 12 years (7 mg capsules);
- for the prevention of recurrent infections of the upper and lower respiratory tract (chronic bronchitis, tonsillitis, pharyngitis, laryngitis, rhinitis, sinusitis, otitis media).
Increased individual sensitivity to the drug.
During the entire period of clinical application of the drug recorded undesirable effects are extremely rare.
In individual cases: disorders of the digestive system (epigastric pain, nausea, vomiting, diarrhea), fever.
If side effects are expressed slightly, discontinuation of the drug is required. When hypersensitivity is recommended removal of the drug reaction.
How to accept, acceptance rate and dosage
Adults and children over 12 years: appoint Broncho-munal® at a dose of 7 mg; children aged 6 months to 12 years: Broncho-munal® P in a dose of 3.5 mg.
The drug is taken on an empty stomach in the morning to 1 kaps. / Day. If the patient / child can not swallow the capsule, it is recommended to open, and the contents of the capsule to dissolve in a small amount of liquid (tea, milk, or juice).
For the prevention of respiratory tract infections: the drug is used with three 10-day courses with 20-day intervals therebetween.
In the acute phase of the disease: assigning 1 caps / day until the disappearance of symptoms, but not less than 10 days.. In the next 2 months possibly prophylactic 1 caps the formulation. for 10 days with 20 days-interval in between courses.
At a temperature of 15-25 ° C
The formulation may be applied simultaneously with other drugs, including antibiotics.
Between the use of oral vaccines and reception Broncho-moon should observe a 4-week interval.
Do not use the drug in acute intestinal diseases due to a possible decrease in efficacy.
Use in Pediatrics
The drug is not indicated for children younger than 6 months. To avoid overdosing children from 6 months to 12 years prescribed only munal® Broncho-P (capsules containing 3.5 mg of lyophilizate).
Effects on ability to drive vehicles and management mechanisms
No special precautions.
Pregnancy and lactation
Application Broncho-munal® the drug during pregnancy and lactation is possible only when the intended benefits to the mother outweighs the potential risk to the fetus or infant.
There was no any clinical symptoms of overdose.
There are no reports of toxicity due to drug overdose.